Orchid Pharma (BOM:524372) Cyclically Adjusted Revenue per Share: ₹172.47 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524372 Orchid Pharma Ltd BOM:524372
60 GF Score
Price ₹1,004.30
GF Value ₹857.65
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Orchid Pharma Cyclically Adjusted Revenue per Share?

Orchid Pharma BOM:524372 +1.72% 60 Cyclically Adjusted Revenue per Share is ₹172.47 as of Mar. 2026. GuruFocus rates BOM:524372 with a GF Score™ of 60/100 and a GF Value™ of ₹857.65 (Modestly Overvalued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Orchid Pharma's adjusted revenue per share for the three months ended in Mar. 2026 was ₹46.862. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹172.47 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Orchid Pharma's average Cyclically Adjusted Revenue Growth Rate was 3.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-04), Orchid Pharma's current stock price is ₹1004.30. Orchid Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₹172.47. Orchid Pharma's Cyclically Adjusted PS Ratio of today is 5.82.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Orchid Pharma was 6.04. The lowest was 2.95. And the median was 4.36.


Orchid Pharma  (BOM:524372) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Orchid Pharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1004.30/172.47
=5.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Orchid Pharma was 6.04. The lowest was 2.95. And the median was 4.36.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Orchid Pharma Cyclically Adjusted Revenue per Share Related Terms


Orchid Pharma Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Orchid Pharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orchid Pharma Cyclically Adjusted Revenue per Share Chart

Orchid Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 166.88 172.47

Orchid Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 166.88 168.08 170.15 170.95 172.47

BOM:524372 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orchid Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orchid Pharma Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orchid Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Orchid Pharma's Cyclically Adjusted PS Ratio falls into.


BOM:524372
60GF Score
Orchid Pharma Ltd BOM:524372
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orchid Pharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Orchid Pharma's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=46.862/164.2724*164.2724
=46.862

Current CPI (Mar. 2026) = 164.2724.

Orchid Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200903 0.000 56.615 0.000
201003 0.000 65.030 0.000
201103 0.000 70.768 0.000
201203 0.000 76.889 0.000
201209 46.899 82.244 93.675
201309 53.552 91.042 96.627
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201709 23.541 109.021 35.471
201803 0.000 109.786 0.000
201809 16.019 115.142 22.854
201903 0.000 118.202 0.000
201906 15.222 120.880 20.686
201909 14.788 123.175 19.722
201912 31.719 126.235 41.277
202003 21.385 124.705 28.170
202006 29.183 127.000 37.748
202009 26.586 130.118 33.565
202012 25.188 130.889 31.612
202103 29.300 131.771 36.527
202106 22.612 134.084 27.703
202109 31.286 135.847 37.832
202112 39.578 138.161 47.058
202203 43.145 138.822 51.055
202206 32.107 142.347 37.052
202209 40.433 144.661 45.914
202212 39.167 145.763 44.141
202303 51.485 146.865 57.587
202306 35.982 150.280 39.332
202309 43.156 151.492 46.797
202312 46.320 152.924 49.757
202403 42.788 153.035 45.930
202406 48.214 155.789 50.839
202409 43.907 157.882 45.684
202412 42.893 158.323 44.505
202503 46.868 157.552 48.867
202506 34.097 159.755 35.061
202509 38.207 162.289 38.674
202512 40.916 163.281 41.164
202603 46.862 164.272 46.862

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹172.47 mean?
Orchid Pharma (BOM:524372) has a Cyclically Adjusted Revenue per Share of ₹172.47 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Orchid Pharma and its competitors.
Is Orchid Pharma's Cyclically Adjusted Revenue per Share too high?
Orchid Pharma's current Cyclically Adjusted Revenue per Share is ₹172.47. Overall, Orchid Pharma has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orchid Pharma's Cyclically Adjusted Revenue per Share compare to ZTS?
Orchid Pharma's Cyclically Adjusted Revenue per Share of ₹172.47 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Orchid Pharma and its competitors. Orchid Pharma's current Cyclically Adjusted Revenue per Share is ₹172.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchid Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orchid Pharma (BOM:524372) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹857.65, compared to a current price of ₹1,004.30 — trading 17.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹172.47. Orchid Pharma's overall GF Score™ is 60/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Orchid Pharma (BOM:524372), the current Cyclically Adjusted Revenue per Share is ₹172.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orchid Pharma (BOM:524372) Overvalued in 2026?

Based on GuruFocus' analysis, Orchid Pharma stock appears to be overvalued. The current stock price of ₹1,004.30 is trading 17.1% above its estimated GF Value™ of ₹857.65. GuruFocus considers Orchid Pharma to be Modestly Overvalued.

Key valuation signals for BOM:524372:

  • Cyclically Adjusted Revenue per Share: ₹172.47
  • GF Value™: ₹857.65 vs. price of ₹1,004.30 (17.1% above fair value)
  • GF Score™: 60/100 with 10 warning signs

No single metric tells the full story. See the BOM:524372 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orchid Pharma Business Description

Other Exchanges ORCHPHARMA:India
Address Sector 74A, 15th Floor, Tower-1, DLF Corporate Greens, Narsinghpur, Gurugram, HR, IND, 122004
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
60GF Score

Get the complete analysis for BOM:524372

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,004.30
Price
₹857.65
GF Value